Clinical trials that include an in vitro diagnostic device

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the use of in vitro diagnostic (IVD) devices and companion diagnostics within clinical trials of medicinal products (CTIMPs) in Great Britain. This regulatory framework applies to all trial sites located in Great Britain, as well as instances where patient samples are analyzed in other jurisdictions if the results directly influence patient management decisions within Great Britain. The guidance provides formal definitions for IVDs and companion diagnostics to ensure clinical trial sponsors understand the classification of the tools used in their research. Because this is a general guidance document rather than an enforcement report, there are no specific company names, inspection dates, or violations listed; however, it outlines critical compliance expectations for all trial applicants. To meet regulatory standards, sponsors must provide supplementary documentation to the MHRA when applying for trial approval. This additional information is necessary for the agency to evaluate the safety and performance of the diagnostic methods used to select or monitor participants. Failure to include these details during the initial application phase may result in delays or rejection of the clinical trial authorization. By following these requirements, sponsors ensure that the diagnostic data used in their trials is robust and meets the legal standards required for clinical research in Great Britain.